A randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorder

BMC Psychiatry

Volumn 9, Issue , 2009, Pages

  Mello, Marcelo Feijó ^a   Yeh, Mary Sau Ling ^a   Neto, Jair Barbosa ^a   Braga, Luciana Lorens ^a   Fiks, Jose Paulo ^a   Mendes, Daniela Deise ^a   Moriyama, Tais S ^a   Valente, Nina Leão Marques ^a   Costa, Mariana Caddrobi Pupo ^a   Mattos, Patricia ^a   Bressan, Rodrigo Affonseca ^a   Andreoli, Sergio Baxter ^a   Mari, Jair Jesus ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; FRUCTOSE;

ADULT; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; POSTTRAUMATIC STRESS DISORDER; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT DURATION; ADOLESCENT; COMPARATIVE STUDY; MIDDLE AGED; PERSONALITY TEST; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; STATISTICS; TREATMENT OUTCOME; WAR;

ADOLESCENT; ADULT; ANTICONVULSANTS; COMBAT DISORDERS; DOUBLE-BLIND METHOD; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME; WAR;

EID: 67650297209     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-9-28     Document Type: Article

References (38)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders Washington DC: APA Fourth 1994
2. Kessler RC Sonnega A Bromet E Hughes M Nelson CB Posttraumatic stress disorder in the National Comorbidity Survey Arch Gen Psychiatry 1995, 52(12):1048-60 7492257
3. Bisson J Andrew M Psychological treatment of post-traumatic stress disorder (PTSD) Cochrane Database of Systematic Reviews 2007, 4:CD003388
4. Bradley R Greene J Russ E Dutra L Westen D A multidimensional metaanalysis of psychotherapy for PTSD American Journal of Psychiatry 2005, 162:214-227 10.1176/appi.ajp.162.2.214 15677582
5. NICE Post-traumatic stress disorder (PTSD) The management of PTSD in adults and children in primary and secondary care Clinical Guideline 26 National Institute for Clinical Excellence London 2005
6. Stein DJ Ipser JC Seedat S Pharmacotherapy for posttraumatic stress disorder Cochrane Database Syst Rev 2006, 25(1):CD002795
7. American Psychiatric Association Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder Washington, DC: APA 2004
8. Stein MB Kline NA Matloff JL Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study Am J Psychiatry 2002, 159:1777-1779 10.1176/appi.ajp.159.10.1777 12359687
9. Petty F Brannan S Casada J Davis LL Gajewski V Kramer GL Stone RC Teten AL Worchel J Young KA Olanzapine treatment for post-traumatic stress disorder: An open label study Int Clin Psychopharmacol 2001, 16:331-337 10.1097/00004850-200111000-00003 11712621
10. Hamner MB Faldowski RA Ulmer HG Frueh BC Huber MG Arana GW Adjunctive risperidone treatment in post-traumatic stress disorder: A preliminary controlled trial of effects on comorbid psychotic symptoms Int Clin Psychopharmacol 2003, 18:1-8 10.1097/00004850-200301000-00001 12490768
11. Lipper S Davidson JR Grady TA Edinger JD Hammett EB Mahorney SL Cavenar JO Jr Preliminary study of carbamazepine in post-traumatic stress disorder Psychosomatics 1986, 27:849-854 3543990
12. Clark RD Canive JM Calais LA Qualls CR Tuason VB Divalproex in posttraumatic stress disorder: An open-label clinical trial J Trauma Stress 1999, 12:395-401 10.1023/A:1024797014210 10378177
13. Fesler FA Valproate in combat-related posttraumatic stress disorder J Clin Psychiatry 1991, 52:361-364 1894587
14. Hertzberg MA Butterfield MI Feldman ME Beckham JC Sutherland SM Connor KM Davidson JR A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder Biol Psychiatry 1999, 45:1226-1229 10.1016/ S0006-3223(99)00011-6 10331117
15. Post RM Weiss SR Smith M Li H McCann U Kindling versus quenching. Implications for the evolution and treatment of posttraumatic stress disorder Ann N Y Acad Sci 1997, 821:285-95 10.1111/ j.1749-6632.1997.tb48287.x 9238212
16. Wauquier A Zhou S Topiramate: A potent anticonvulsant in the amygdala-kindled rat Epilepsy Res 1996, 24(2):73-7 10.1016/ 0920-1211(95)00105-0 8796355
17. Trujillo KA Akil H Excitatory amino acids and drugs of abuse: A role for N methyl-D-aspartate receptors in drug tolerance, sensitization and physical dependence Drug Alcohol Depend 1995, 38(2):139-154 10.1016/ 0376-8716(95)01119-J 7671766
18. Shank RP Joseph FG Streeter AJ Maryanoff BE An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action Epilepsia 2000, 41(Suppl. 1):S3-S9 10.1111/ j.1528-1157.2000.tb06045.x 10768292
19. Zullino DF Krenz S Besson J AMPA blockade may be the mechanism underlying the efficacy of topiramate in PTSD J Clin Psychiatry 2003, 64(2):219-220 12633137
20. Khan S Liberzon I Topiramate attenuates exaggerated acoustic startle in an animal model of PTSD Psychopharmacology (Berl) 2004, 172(2):225-9 10.1007/s00213-003-1634-4 14586539
21. Joca SR Ferreira FR Guimaraes FS Modulation of stress consequences by hippocampal monoaminergic, glutamatergic and nitrergic neurotransmitter systems Stress 2007, 10(3):227-249 10.1080/10253890701223130 17613938
22. Rose S Bisson J Churchill R Wesseley S Psychological debriefing for preventing posttraumatic stress disorder (PTSD) Cochrane Database Syst Rev 2002, 2:CD000560 12076399
23. Sherman JJ Effects of psychotherapeutic treatments for PTSD: A metaanalysis of controlled clinical trials J Trauma Stress 1998, 11(3):413-35 10.1023/A:1024444410595 9690185
24. Lee JL Milton AL Everitt BJ Reconsolidation and extinction of conditioned fear: Inhibition and potentiation J Neurosci 2006, 26(39):10051-6 10.1523/JNEUROSCI.2466-06.2006 17005868
25. Heldt SA Ressler KJ Training-induced changes in the expression of GABAA-associated genes in the amygdala after the acquisition and extinction of Pavlovian fear Eur J Neurosci 2007, 26(12):3631-44 2443698 18088283
26. Stork O Ji FY Obata K Reduction of extracellular GABA in the mouse amygdala during and following confrontation with a conditioned fear stimulus Neurosci Lett 2002, 327(2):138-142 10.1016/ S0304-3940(02)00387-7 12098654
27. Berlant J van Kammen DP Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: A preliminary report J Clin Psychiatry 2002, 63(1):15-20 11838620
28. Berlant J Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder BMC Psychiatry 2004, 4:24 516778 15315714 10.1186/ 1471-244X-4-24
29. Tucker P Trautmann RP Wyatt DB Thompson J Wu SC Capece JA Rosenthal NR Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: A randomized, double-blind, placebocontrolled study J Clin Psychiatry 2007, 68(2):201-6 17335317
30. Lindley SE Carlson EB Hill K A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combatrelated posttraumatic stress disorder J Clin Psychopharmacol 2007, 27(6):677-81 10.1097/jcp.0b013e31815a43ee 18004136
31. Spitzer RL Williams JB Gibbon M First MB The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description Arch Gen Psychiatry 1992, 49(8):624-9 1637252
32. First M Spitzer RL Gibbon M Williams JBW The structured clinical interview for DSM-III-R personality disorders (SCID-II). Part I: Description J Personal Disord 1995, 9:2
33. Blake DD Weathers FW Nagy LM Kaloupek DG Gusman FD Charney DS Keane TM The development of a Clinician-Administered PTSD Scale J Trauma Stress 1995, 8(1):75-90 10.1002/jts.2490080106 7712061
34. Beck AT Ward CH Mendelson M Mock J Erbaugh J An inventory for measuring depression Arch Gen Psychiatry 1961, 4:561-71 13688369
35. McHorney CA Ware JE Jr Raczek AE The MOS 36-Item Short- Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs Med Care 1993, 31(3):247-63 10.1097/00005650-199303000-00006 8450681
36. Bosc M Dubini A Polin V Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale Eur Neuropsychopharmacol 1997, 7(Suppl 1):S57-70 discussion S71-3. 10.1016/ S0924-977X(97)00420-3 9169311
37. Ramirez A Ekselius L Ramklint M Axis V - Global Assessment of Functioning Scale (GAF), further evaluation of the self-report version Eur Psychiatry 2008, 23(8):575-9 10.1016/j.eurpsy.2008.05.001 18774271
38. Guy W Cleary PA Pretreatment status and its relationship to the length of drying-out period Psychopharmacol Bull 1976, 12(2):20-2 1257387